Compare Moderna, Inc. (MRNA) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Warner Music Group Corp — how do they compare? Moderna, Inc. trades at $136.5 (market cap $54.14B), while Warner Music Group Corp trades at $28.16 (market cap $14.73B). The key difference: Moderna, Inc. is far larger — about 3.7× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.84% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WMG | |
|---|---|---|
Market Cap | $54.14B | $14.73B |
Sector | Health | Media |
52-Week High | $174.38 | $34.72 |
52-Week Low | $22.36 | $23.65 |
Enterprise Value | $50.29B | $19.03B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent quarterly earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, and recent news highlights AI partnerships and licensing renewals.
Outlook is positive due to strong streaming growth and strategic AI initiatives, but risks include margin pressure and leadership changes. The stock offers value with a P/E of 22.42 and robust cash flow, though near-term volatility may persist amid market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
